José Elias Miziara

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Silvia Novello, Joachim von Pawel et al. · Journal of Clinical Oncology · 2010 · 454 citations · Full text

Medicine, Oncology, Pharmacology +17

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczęsna et al. · Journal of Clinical Oncology · 2012 · 212 citations

Medicine, Oncology, Pharmacology +17

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Luis Paz‐Ares, J. Mezger, Tudor–Eliade Ciuleanu et al. · The Lancet Oncology · 2015 · 131 citations · Full text

Medicine, Oncology, Pharmacology +13

Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

Jianxing He, Masahiro Tsuboi, Walter Weder et al. · Journal of Clinical Oncology · 2025 · 61 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations

Letícia Ferro Leal, Flávia Escremim de Paula, Pedro De Marchi et al. · Scientific Reports · 2019 · 48 citations · Full text

Medicine, Genetics, Oncology +15